Traduction de «available information about » (Néerlandais → Français) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

To learn more about our commitments, please visit us at www.pfizer.com. More information is available at www.pfizer.com.
To learn more about our commitments, please visit us at www.pfizer.com .More information is available at www.pfizer.com.

Information about sample availability e-mail ech_staal@fagg-afmps.be
Information about sample availability e-mail ech_staal@fagg-afmps.be

Based on an evaluation of publicly available information about Alcon during the first half of 2009, no factors indicated that the “value in use” of this strategic investment to Novartis has fallen below the current carrying value of USD 136.84 per share (The revised carrying value from the previous level of USD 140.58 at the end of the first quarter of 2009 takes into account dividends paid in 2009 as well as other equity accounting adjustments).
Sur la base d’une évaluation des informations publiées sur Alcon au cours du premier semestre 2009, aucun facteur n’indiquait que pour Novartis, la valeur d’utilité de cet investissement stratégique était tombée en dessous de la valeur comptable d’USD 136,84 par action (cette valeur comptable inscrite au bilan et révisée par rapport à la valeur d’USD 140,58 à la fin du premier trimestre 2009, suite aux dividendes payés en 2009 ainsi que d’autres ajustements comptables résultant de l’application de la méthode de la mise en équivalence).